Dr George Sharbeen is deputy lead of the Pancreatic Cancer Translational Research Group (UNSW Sydney). His research is focused on developing more effective therapies for pancreatic cancer and his most notable achievements include co-development of a novel nanomedicine for pancreatic cancer and a 3D human pancreatic cancer explant model, and the identification of an amino acid transporter as a stromal remodelling target in pancreatic cancer (Sharbeen et al, Cancer Research, 2021). His work formed the foundation for the SPEAR trial (Sulfasalazine in patients with PancrEatic AdenocaRcinoma) clinical trial (led by Prof Phoebe Phillips and Prof David Goldstein; part of the Molecular Screening and Therapeutics [MoST] pancreas cancer program) where Dr Sharbeen leads the correlative science studies. His research success has been recognised by a number of awards and competitive research funding including Cancer-Institute NSW Early-Career and Mid-Career Fellowships. He is currently funded an NHMRC Ideas grant, Pankind Accelerator grants and a Tour de Cure Pioneering Research grant, and is senior research fellow for the Poor Outcomes Cancers focus area in the Sydney Partnership for Health, Education, Research and Enterprise [SPHERE] Cancer Clinical Academic Group.